Product Description
For Malignant Glioma
Mechanisms of Action: DNA Synthesis Inhibitor, RNA Transcription Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nobelpharma
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glioblastoma|Glioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00919737 |
NPC-08-1 | P2 |
Completed |
Glioblastoma|Glioma |
2011-04-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|